Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO1999057141) IMMUNODIAGNOSTIC REAGENT FOR THE DETECTION OF MAEDI-VISNA VIRUS AND CAEV INFECTION
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/1999/057141 International Application No.: PCT/EP1999/002810
Publication Date: 11.11.1999 International Filing Date: 26.04.1999
Chapter 2 Demand Filed: 22.11.1999
IPC:
C07K 14/155 (2006.01) ,G01N 33/531 (2006.01) ,G01N 33/569 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005
from viruses
08
RNA viruses
15
Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
155
Lentiviridae, e.g. human immunodeficiency virus (HIV), visna-maedi virus, equine infectious anaemia virus
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
531
Production of immunochemical test materials
G PHYSICS
01
MEASURING; TESTING
N
INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33
Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48
Biological material, e.g. blood, urine; Haemocytometers
50
Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53
Immunoassay; Biospecific binding assay; Materials therefor
569
for micro-organisms, e.g. protozoa, bacteria, viruses
Applicants:
GONZALEZ, Lorenzo [ES/GB]; GB (UsOnly)
TOLARI, Francesco [IT/IT]; IT (UsOnly)
WATT, Neil [GB/GB]; GB (UsOnly)
HARKISS, Gordon [GB/GB]; GB (UsOnly)
AMORENA, Beatriz [ES/ES]; ES (UsOnly)
SAMAN, Eric [BE/BE]; BE (UsOnly)
VAN EYNDE, Geertrui [BE/BE]; BE (UsOnly)
BADIOLA DIEZ, Juan José [ES/ES]; ES (UsOnly)
EXTRAMIANA, Belén [ES/ES]; ES (UsOnly)
BOLLO, Enrico [IT/IT]; IT (UsOnly)
JUSTE, Ramon, A. [ES/ES]; ES (UsOnly)
INNOGENETICS N.V. [BE/BE]; Industriepark Zwijnaarde 7 Box 4 B-9052 Ghent, BE (AllExceptUS)
Inventors:
GONZALEZ, Lorenzo; GB
TOLARI, Francesco; IT
WATT, Neil; GB
HARKISS, Gordon; GB
AMORENA, Beatriz; ES
SAMAN, Eric; BE
VAN EYNDE, Geertrui; BE
BADIOLA DIEZ, Juan José; ES
EXTRAMIANA, Belén; ES
BOLLO, Enrico; IT
JUSTE, Ramon, A.; ES
Priority Data:
98870101.730.04.1998EP
Title (EN) IMMUNODIAGNOSTIC REAGENT FOR THE DETECTION OF MAEDI-VISNA VIRUS AND CAEV INFECTION
(FR) REACTIF D'IMMUNODIAGNOSTIC POUR LA DETECTION D'UNE INFECTION PAR LE VIRUS MAEDI-VISNA ET LE VIRUS ARTHRITE-ENCEPHALITE CAPRINE
Abstract:
(EN) The current invention relates to a biotinylated peptide represented by the following formula: [B1 -L1] - (a) - CWHYX9X10YC- (b) - [L2- B2] (SEQ ID NO 83) wherein B represents a biotinyl moiety and L represents an amide bond or an amino acid linker sequence containing from 1 to 5 amino acid residues, with either [B1 -L1] or [L2 -B2] present or both, and wherein (a) represents from none to the maximum number of contiguous amino acids located from position 1 to position 4 in the sequence represented by SEQ ID NO 12, and wherein (b) represents from none to the maximum number of contiguous amino acids located from position 13 to position 18 in the sequence represented by SEQ ID NO 12.
(FR) L'invention concerne un peptide biotinylé représenté par la formule générale [B1 -L1] - (a) - CWHYX9X10YC- (b) - [L2- B2] (identificateur de séquence SEQ ID N° 83), dans laquelle B est une fraction biotiynle et L est une liaison amide ou une séquence de liaison d'acides aminés contenant entre 1 et 5 résidus d'acides aminés, avec la présence de [B1 -L1] ou de [L2- B2] ou des deux à la fois. Par ailleurs, dans ladite formule, (a) est un nombre d'acides aminés contigus allant de zéro au maximum, ces résidus ayant un emplacement qui va de la position 1 à la position 4 dans la séquence représentée par l'identificateur de séquence SEQ ID N° 12, et (b) est un nombre d'acides aminés contigus allant de zéro au maximum, ces résidus ayant un emplacement qui va de la position 13 à la position 18 dans la séquence représentée par l'identificateur de séquence SEQ ID N° 12.
Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW
African Regional Intellectual Property Organization (ARIPO) (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (EPO) (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)